Chan Joon Kim1, Ik-Jun Choi2, Hun-Jun Park3, Tae Hoon Kim3, Pum-Joon Kim3, Kiyuk Chang3, Sang Hong Baek3, Wook Sung Chung3, Ki-Bae Seung3. 1. Division of Cardiology, Department of Internal Medicine, Daejon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea. 2. Division of Cardiology, Department of Internal Medicine, Inchon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Inchon, Republic of Korea. 3. Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Abstract
BACKGROUND: Dysfunctional interplay between the heart and kidneys may lead to the development of anemia. The aim of this study was to evaluate the impact of cardiorenal anemia syndrome (CRAS) on short- and long-term outcomes among patients hospitalized with heart failure (HF). METHODS: We enrolled 303 patients hospitalized with HF. We divided the patients into two groups: a CRAS group (n = 64) and a non-CRAS group (n = 239). We defined CRAS as HF accompanied by (1) an estimated glomerular filtration rate <60 ml/min/1.73 m(2) calculated by the Modification of Diet in Renal Disease at admission and (2) a hemoglobin level <12 g/dl for females and <13 g/dl for males at admission. The primary outcome was a composite of cardiac death, non-fatal myocardial infarction and rehospitalization for HF. RESULTS: During a median follow-up period of 25.6 months (range 0.1-35.3 months), the patients with CRAS had a significantly increased risk for the primary outcome (27.5 vs. 10.7%, p < 0.001) compared with the patients in the non-CRAS group. Using Cox proportional hazard analyses, the hazard ratio (HR) for the presence of CRAS was found to be 1.874 (95% confidence interval [CI] 1.011-3.475, p = 0.046); HRs were also computed for the presence of diabetes mellitus (HR = 2.241, 95% CI 1.221-4.112, p = 0.009), New York Heart Association class III or IV HF (HR = 2.948, 95% CI 1.206-7.205, p = 0.018) and the use of intravenous loop diuretics (HR = 2.286, 95% CI 0.926-5.641, p = 0.073). CONCLUSIONS: Renal dysfunction and anemia are a fatal combination and are associated with poor prognosis in patients with HF.
BACKGROUND: Dysfunctional interplay between the heart and kidneys may lead to the development of anemia. The aim of this study was to evaluate the impact of cardiorenal anemia syndrome (CRAS) on short- and long-term outcomes among patients hospitalized with heart failure (HF). METHODS: We enrolled 303 patients hospitalized with HF. We divided the patients into two groups: a CRAS group (n = 64) and a non-CRAS group (n = 239). We defined CRAS as HF accompanied by (1) an estimated glomerular filtration rate <60 ml/min/1.73 m(2) calculated by the Modification of Diet in Renal Disease at admission and (2) a hemoglobin level <12 g/dl for females and <13 g/dl for males at admission. The primary outcome was a composite of cardiac death, non-fatal myocardial infarction and rehospitalization for HF. RESULTS: During a median follow-up period of 25.6 months (range 0.1-35.3 months), the patients with CRAS had a significantly increased risk for the primary outcome (27.5 vs. 10.7%, p < 0.001) compared with the patients in the non-CRAS group. Using Cox proportional hazard analyses, the hazard ratio (HR) for the presence of CRAS was found to be 1.874 (95% confidence interval [CI] 1.011-3.475, p = 0.046); HRs were also computed for the presence of diabetes mellitus (HR = 2.241, 95% CI 1.221-4.112, p = 0.009), New York Heart Association class III or IV HF (HR = 2.948, 95% CI 1.206-7.205, p = 0.018) and the use of intravenous loop diuretics (HR = 2.286, 95% CI 0.926-5.641, p = 0.073). CONCLUSIONS:Renal dysfunction and anemia are a fatal combination and are associated with poor prognosis in patients with HF.
Authors: Alan S Go; Jingrong Yang; Lynn M Ackerson; Krista Lepper; Sean Robbins; Barry M Massie; Michael G Shlipak Journal: Circulation Date: 2006-06-05 Impact factor: 29.690
Authors: Liviu Klein; Christopher M O'Connor; Jeffrey D Leimberger; Wendy Gattis-Stough; Ileana L Piña; G Michael Felker; Kirkwood F Adams; Robert M Califf; Mihai Gheorghiade Journal: Circulation Date: 2005-05-02 Impact factor: 29.690
Authors: G Michael Felker; Kerry L Lee; David A Bull; Margaret M Redfield; Lynne W Stevenson; Steven R Goldsmith; Martin M LeWinter; Anita Deswal; Jean L Rouleau; Elizabeth O Ofili; Kevin J Anstrom; Adrian F Hernandez; Steven E McNulty; Eric J Velazquez; Abdallah G Kfoury; Horng H Chen; Michael M Givertz; Marc J Semigran; Bradley A Bart; Alice M Mascette; Eugene Braunwald; Christopher M O'Connor Journal: N Engl J Med Date: 2011-03-03 Impact factor: 91.245
Authors: D S Silverberg; D Wexler; M Blum; G Keren; D Sheps; E Leibovitch; D Brosh; S Laniado; D Schwartz; T Yachnin; I Shapira; D Gavish; R Baruch; B Koifman; C Kaplan; S Steinbruch; A Iaina Journal: J Am Coll Cardiol Date: 2000-06 Impact factor: 24.094
Authors: H L Hillege; A R Girbes; P J de Kam; F Boomsma; D de Zeeuw; A Charlesworth; J R Hampton; D J van Veldhuisen Journal: Circulation Date: 2000-07-11 Impact factor: 29.690
Authors: Maria Rosa Costanzo; Maya E Guglin; Mitchell T Saltzberg; Mariell L Jessup; Bradley A Bart; John R Teerlink; Brian E Jaski; James C Fang; Erika D Feller; Garrie J Haas; Allen S Anderson; Michael P Schollmeyer; Paul A Sobotka Journal: J Am Coll Cardiol Date: 2007-01-26 Impact factor: 24.094
Authors: Ridha I S Alnuwaysir; Niels Grote Beverborg; Martijn F Hoes; George Markousis-Mavrogenis; Karla A Gomez; Haye H van der Wal; John G F Cleland; Kenneth Dickstein; Chim C Lang; Leong L Ng; Piotr Ponikowski; Stefan D Anker; Dirk J van Veldhuisen; Adriaan A Voors; Peter van der Meer Journal: Eur J Heart Fail Date: 2021-12-09 Impact factor: 17.349